<DOC>
	<DOCNO>NCT02315157</DOCNO>
	<brief_summary>This phase I trial study side effect best dose bendamustine hydrochloride treat patient previously treat multiple myeloma . Drugs use chemotherapy , bendamustine hydrochloride , work different way stop growth cancer cell , either kill cell , stop dividing , stop spreading .</brief_summary>
	<brief_title>Bendamustine Hydrochloride Treating Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To identify maximum tolerate dose bendamustine ( bendamustine hydrochloride ) patient multiple myeloma . SECONDARY OBJECTIVES : I . To evaluate safety escalate dos bendamustine patient multiple myeloma . II . To describe response bendamustine OUTLINE : This dose-escalation study . Patients receive bendamustine hydrochloride intravenously ( IV ) 60-180 minute day 1 2 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Patients multiple myeloma achieve CR follow least 4 cycle induction therapy 2 . Age 80 year 3 . ECOG Performance Status 0 1 4 . Left ventricular ejection fraction =/ &gt; 40 % . No uncontrolled arrhythmias symptomatic cardiac disease 5 . FEV1 , FVC DLCO =/ &gt; 40 % . No symptomatic pulmonary disease . 6 . Serum bilirubin &lt; 2 x upper limit normal , alkaline phosphatase &lt; 3 x upper limit normal . No evidence chronic active hepatitis cirrhosis . No effusion ascites &gt; 1 L prior drainage . 7 . HIV negative 8 . Negative beta HCG test woman child bear potential , define postmenopausal 12 month previous sterilization 9 . Patients guardian able sign inform consent 10 . Availability previously collect autologous stem cell ( least 3.0 x 106 CD34 cells/kg ) 11 . Calculated GFR &gt; 50 ml/minute 1 . Patients uncontrolled hypertension ( systolic &gt; 140 , diastolic &gt; 90 despite antihypertensive therapy 2 . Patients uncontrolled bacteria , viral fungal infection ( currently take medication progression clinical symptom ) 3 . New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities 4 . Relapsed/refractory myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Partial Response</keyword>
</DOC>